Table 2. Summary of best cytogenetic and hematologic responses for patients treated with any dose of MK-0457.
| Best response, n (%) | Chronic phase CML n=15 | Accelerated phase CML n=14 | Blast phase CML n=11 | Ph+ ALL n=12 | All patients n=52 |
|---|---|---|---|---|---|
| Best cytogenetic response | |||||
| Major response | 2 (13.3) | 1 (7.1) | 1 (9.1) | 0 (0.0) | 4 (7.7) |
| Complete response | 1 (6.7)a | 1 (7.1)b | 0 (0.0) | 0 (0.0) | 2 (3.8) |
| Partial response | 1 (6.7)a | 0 (0.0) | 1 (9.1)c | 0 (0.0) | 2 (3.8) |
| Unconfirmed complete response | 0 (0.0) | 1 (7.1)a | 0 (0.0) | 1 (8.3)a | 2 (3.8) |
| Unconfirmed partial response | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (8.3)a | 1 (1.9) |
| No response | 6 (40.0) | 8 (57.1) | 3 (27.3) | 3 (25.0) | 20 (38.5) |
| No valid cytogenetic measurement | 7 (46.7) | 4 (28.6) | 7 (63.6) | 7 (58.3) | 25 (48.1) |
| Best hematologic response | |||||
| Major response | NA | 0 (0.0) | 0 (0) | 0 (0.0) | 0 (0) |
| Complete response | 2 (13.3)a | 0 (0.0) | 0 (0) | 0 (0.0) | 2 (3.8) |
| Unconfirmed NEL | NA | 0 (0.0) | 0 (0) | 1 (8.3)b | 1 (1.9) |
| Minor response | NA | 4 (28.6)d | 0 (0) | 1 (8.3)a | 5 (9.6) |
| No response | 0 (0.0) | 10 (71.4) | 11 (100.0) | 10 (83.3) | 31 (59.6) |
| No valid hematologic measurement | 13 (86.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (25.0) |
Abbreviations: CML, chronic myelogenous leukemia; NA, not applicable; NEL, no evidence of leukemia; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukemia.
Treatment started at 40 mg/m2/h.
Treatment started at 24 mg/m2/h.
Treatment started at 32 mg/m2/h.
Treatment started at 40 mg/m2/h for three patients and 32 mg/m2/h for one patient.